Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Takaoka T, Kimura T, Shimoyama R, Kawamoto S, Sakamoto K, Goda F, Miyamoto H, Negoro Y, Tsuji A, Yoshizaki K, Goji T, Kitamura S, Yano H, Okamoto K, Kimura M, Okahisa T, Muguruma N, Niitsu Y, Takayama T.
Takaoka T, et al. Among authors: miyamoto h.
Cancer Chemother Pharmacol. 2016 Aug;78(2):397-403. doi: 10.1007/s00280-016-3096-5. Epub 2016 Jun 24.
Cancer Chemother Pharmacol. 2016.
PMID: 27342247
Clinical Trial.